Verified factor-similar pair

DFAS vs FYX

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
90
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • DFAS has the higher backtested relative Sharpe (1.158 vs 0.958).
  • DFAS has the lower published fee (0.26% vs 0.58%).
  • FYX is cheaper on dividend valuation (95 vs 106, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

DFAS

Dimensional U.S. Small Cap ETF
SMB
Adj. R2
0.980
Rel. Sharpe
1.158
Mkt beta
1.00
AUM
US$13.4B
MER
0.26%
Valuation
106

FYX

First Trust Small Cap Core Alphadex Fund
SMB
Adj. R2
0.977
Rel. Sharpe
0.958
Mkt beta
1.02
AUM
US$1.1B
MER
0.58%
Valuation
95

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
DFAS
+0.85
|t|
+20.1
FYX
+0.97
|t|
+34.2
diff -0.12
HML
DFAS
+0.20
|t|
+4.5
FYX
+0.19
|t|
+7.0
diff +0.00
RMW
DFAS
+0.18
|t|
+4.5
FYX
+0.14
|t|
+4.3
diff +0.03
CMA
DFAS
+0.03
|t|
+0.6
FYX
-0.02
|t|
-0.6
diff +0.06
UMD
DFAS
+0.03
|t|
+1.1
FYX
-0.01
|t|
-0.9
diff +0.05

Why This Pair Matches

Exposure level
89
Exposure shape
100
Mkt beta diff
0.02
Rel. Sharpe diff
0.200

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

DFAS fund page FYX fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.